Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone. (Source: Drug Development Technology)
Orexo starts patient dosing in Phase III study of opioid dependence drug
Previous post: Buprenorphine therapy: an increasing challenge in oral and maxillofacial surgery
Next post: First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland
